Abstracts tagged "Lupus"

Abstract Number: 2124 • 2018 ACR/ARHP Annual Meeting
Bacterial Biofilm Product Curli/Edna Induces NETs and Serum Anti-Curli/Edna Levels Correlate with Bacteriuria and Lupus Activity
Ryan Pachucki¹, Chelsea Corradetti², Stefania Gallucci³, Cagla Tukel³, Sarah Tursi³, Laura Nicastro³, Lynne Kohler², Yaj Ghadiali⁴, Laurie Kilpatrick⁵ and Roberto Caricchio¹, ¹Medicine Rheumatology, Lewis Katz School of Medicine, Philadelphia, PA, ²Rheumatology, Lewis Katz School of Medicine, Philadelphia, PA, ³Microbiology and Immunology, Lewis Katz School of Medicine, Philadelphia, PA, ⁴Medicine, Lewis Katz School of Medicine, Philadelphia, PA, ⁵Temple Lung Center, Lewis Katz School of Medicine, Philadelphia, PA
Background/Purpose: Infections are a major contributor to lupus disease. We have previously demonstrated that bacterial amyloid curli, produced by E.coli, can accelerate disease in mouse…
Abstract Number: 2846 • 2018 ACR/ARHP Annual Meeting
Foot and Lower Limb Characteristics in People with SLE: A Comparison with Age- and Sex-Matched Healthy Control Participants
Sarah Stewart¹, Ashok Aiyer², Nicola Dalbeth³ and Keith Rome⁴, ¹School of Podiatry, Auckland University of Technology, Auckland, New Zealand, ²School of Podiatry, The Auckland University of Technology, Auckland, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴School of Clinical Science, Health & Rehabilitation Research Institute, AUT University, Auckland, New Zealand
Background/Purpose: People with SLE report joint pain and swelling, impaired circulation, cutaneous lesions and foot deformity. Foot- and lower-limb-related functional impairment has also been described…
Abstract Number: 468 • 2018 ACR/ARHP Annual Meeting
Baseline Features and Outcomes of Pediatric-Onset Discoid Lupus Erythematosus: Interim Data Analysis of a Multicenter Retrospective Cohort Study
Lisa Arkin¹, Kevin A. Buhr², Cordellia Nguyen³, Heather Brandling-Bennett⁴, Leslie Castelo-Soccio⁵, Yvonne Chiu⁶, Benjamin F. Chong⁷, Lucia Diaz⁸, Marisa S. Klein-Gitelman⁹, Amy Paller¹⁰, Jennifer Schoch¹¹, Emily von Scheven¹², Victoria P. Werth¹³, Julie Grossman-Kranseler¹⁴, Andrew D. Hudson¹⁵, Erin M. Ibler¹⁶, Mariana C. Marques¹⁷, Reesa L. Monir¹¹, Elana Putterman¹⁸ and Kaveh Ardalan¹⁹, ¹Departments of Dermatology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Department of Biostatistics & Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Division of Dermatology; Department of Pediatrics, Seattle Children’s Hospital/University of Washington School of Medicine, Seattle, WA, ⁵Pediatrics, Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Pediatrics and Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁷Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁸Department of Pediatrics, Division of Dermatology, Dell Children’s Hospital, Austin, TX, ⁹Department of Pediatrics, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁰Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ¹¹Department of Dermatology, University of Florida School of Medicine, Gainesville, FL, ¹²Department of Pediatrics, Division of Rheumatology, University of California at San Francisco, San Francisco, CA, ¹³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁴Departments of Pediatrics, Division of Dermatology, University of Washington School of Medicine, Seattle, WA, ¹⁵Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, ¹⁶Departments of Dermatology and Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ¹⁷Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁸Children’s Hospital of Philadelphia, Department of Pediatrics, Section of Dermatology, Children’s Hospital of Philadelphia, Philadelphia, PA, ¹⁹Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: Discoid lupus erythematosus (DLE) is rare in children. Prior studies suggest 25-30% of children with skin-limited DLE are diagnosed with systemic lupus erythematosus (SLE)…
Abstract Number: 763 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis
Kubra Bugdayli¹, Cynthia S. Crowson², Ladan Zand³, Mariam P. Alexander⁴, Lynn D. Cornell⁴ and Vaidehi R. Chowdhary⁵, ¹Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ⁴Anatomic Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Comparison of clinical characteristics and outcome between isolated and classic lupus nephritisBackground/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely,…
Abstract Number: 1843 • 2018 ACR/ARHP Annual Meeting
Improving Access to Rheumatology Care for High-Risk Lupus Patients Can Help Decrease Hospitalizations
Allen P. Anandarajah¹, Sean McMahon², Amanda Ostronic³, Changyong Feng⁴, Jennifer Anolik⁵ and Christopher T. Ritchlin⁶, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Quality office, University of Rochester Medical Center, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY, ⁴Statistics, University of Rochester, Rochester, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: We previously demonstrated that a small group of high risk, high cost patients (HRHC) account for majority of the hospitalizations, length of stay (LOS)…
Abstract Number: 2126 • 2018 ACR/ARHP Annual Meeting
STAT4 Activation By Type I Interferons Regulates Pathogenic IL-21 and IFN-γ in Lupus
Xuemei Dong¹, Fotios Koumpouras², Joseph E. Craft³ and Jason Weinstein¹, ¹Rheumatology, Yale University School of Medicine, New Haven, CT, ²Internal Medicine, Rheumatology, Yale University School of Medicine, New Haven, CT, ³Department of Internal Medicine/Rheumatology, Yale University School of Medicine, New Haven, CT
Background/Purpose: Follicular helper T cells (Tfh) cells in lupus help shape the germinal center (GC) response by delivering contact-dependent and soluble signals, including the cytokines…
Abstract Number: 2851 • 2018 ACR/ARHP Annual Meeting
NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Justine Shum¹, Leal Herlitz² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Cleveland Clinic, Cleveland, OH, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Immune-mediated glomerulonephritis is a serious end organ pathology that commonly affects patients with systemic lupus erythematosus (SLE). Nephrotoxic serum nephritis, induced by passive transfer…
Abstract Number: 473 • 2018 ACR/ARHP Annual Meeting
A Weighty Diagnosis: Weight Change and Risk Factors in Early Juvenile Systemic Lupus Erythematosus
Erin Treemarcki¹, Jackie Szymonifka², Alexa Adams³, Nancy Pan⁴, Sarah Taber⁵ and Karen Onel⁵, ¹Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY
Background/Purpose: SLE is a chronic, multisystem autoimmune condition with multiple comorbidities due to inflammation and treatment, including metabolic syndrome, poor cardiac outcome, and poor quality…
Abstract Number: 766 • 2018 ACR/ARHP Annual Meeting
Neutrophil Extracellular Traps Are a Source of Extracellular High Mobility Group Box-1: Association with Clinical and Histopathological Features in Patients with Lupus Nephritis
Laura Patricia Whittall¹, Diana Gómez-Martín¹, Jiram Torres-Ruíz², Alejandro Zentella Dehesa¹, Miguel Tapia-Rodríguez¹ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Current evidence suggests that neutrophils play an important role in the pathophysiology of lupus nephritis (LN) mainly through the secretion of type I IFN…
Abstract Number: 1871 • 2018 ACR/ARHP Annual Meeting
A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE
Maureen A. McMahon¹, Jennifer M. Grossman², Lori Sahakian³, Christina Charles-Schoeman⁴, John Fitzgerald¹, Mihaela Taylor⁴, Alan Gorn¹, Eloise Olmos¹, Daniel J. Wallace⁵, Bevra H Hahn^1,4 and Brian Skaggs⁴, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: There is a well-documented increase in atherosclerosis (ATH) in SLE that is not fully explained by traditional risk factors. Several non-Framingham biomarkers, including pro-inflammatory…
Abstract Number: 2129 • 2018 ACR/ARHP Annual Meeting
Precipitating Anti-dsDNA Peptide Repertoires in Lupus
Jing Jing Wang¹, Alexander Colella¹, Dimitra Beroukas², Tim Chataway³ and Tom Gordon^1,4, ¹Immunology, Flinders University, Adelaide, Australia, ²Immunology, SA Pathology, Adelaide, AR, Australia, ³Proteomic Facility, Flinders University, Adelaide, Australia, ⁴Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Anti-double-stranded (ds)DNA autoantibodies are prototypic serological markers of systemic lupus erythematosus (SLE) but little is known about their immunoglobulin variable (IgV) region composition at…
Abstract Number: 2892 • 2018 ACR/ARHP Annual Meeting
Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
Chi Chiu Mok¹, Kwok Hung Chan², Ling Yin Ho³ and Patrick Chiu Yat Woo², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Microbiology, University of Hong Kong, Hong Kong, Hong Kong, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate the safety and immune response of a live attenuated herpes zoster (HZ) vaccine in patients with SLE by a randomized placebo-control trial…
Abstract Number: 474 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
Suhas Ganguli¹, Joyce Hui-Yuen¹, Meenakshi Jolly^2,3, Jane Cerise⁴ and B. Anne Eberhard⁵, ¹Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ²Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Biostatistics, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Pediatric Rheumatology, Cohen Children's Medical Center, New Hyde Park, NY
Background/Purpose: Patient Reported Outcome (PRO) measures for Quality of Life (QoL) in patients with lupus are useful supplements to the physician-derived indices of disease activity…
Abstract Number: 939 • 2018 ACR/ARHP Annual Meeting
Rab4A Protects from Lupus Nephritis By Limiting Germinal Center Formation and Pro-Inflammatory Expression of GLUT1 and Integrin By Renal Epithelial Cells
Gourav Choudhary¹, Nick Huang², Ryan Kelly³, Thomas Winans⁴, Manuel Duarte², Mark Haas⁵ and Andras Perl², ¹Department of Biochemistry and Mol. Biology, SUNY Upstate Medical University, Syracuse, NY, ²Medicine, SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY, ⁴SUNY Upstate Medical University, Syracuse, NY, ⁵Professor of Pathology, Cedars-Sinai, Los Angeles, CA
Background/Purpose: Lupus nephritis is most common cause of mortality and morbidity in systemic lupus erythematosus (SLE) patients and 60% of SLE patients develops lupus nephritis.…
Abstract Number: 1874 • 2018 ACR/ARHP Annual Meeting
Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort
Guillermo J. Pons-Estel^1,2, Graciela S. Alarcón³, Manuel Ugarte-Gil^4,5, Luis M. Vilá⁶, John D. Reveille⁷ and Gerald McGwin³, ¹Rheumatology, Hospital Provincial de Rosario, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Universidad Científica del Sur, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁷McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Over the last few years the importance of treating patients with SLE towards achieving either Remission or LDAS (Treat-to-Target approach) has become evident. We…

« Previous Page
1
…
7
8
9
10
11
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].